Investor Relations

ENHANCING SHAREHOLDER VALUE THROUGH EXCEPTIONAL BUSINESS PERFORMANCE AND PRACTICES, AND THROUGH RESPONSIBLE AND EFFECTIVE COMMUNICATION WITH ITS SHAREHOLDERS.

Overview.

Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa™ Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa™ Platform has achieved positive results at preclinical studies conducted at the University of Miami.

HOTH
NASDAQ

VOLUME
CHANGE

Investor Updates.

Keep up to date on Hoth Therapeutics News. Simply fill out your
email below and you will be added to our email newsletter.


By clicking submit, you are agreeing to our Terms & Conditions